Current treatment status-Undergoing active treatment-Progressive despite treatment - Page 14 of 29 Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment-Progressive despite treatment Posts on Medivizor

Use of specific T-cells in the treatment of ALL

Use of specific T-cells in the treatment of ALL

Posted by on Nov 25, 2018 in Leukemia | 0 comments

In a nutshell This study looked at the use of specific T-cells to treat acute lymphoblastic leukemia. Researchers found that using these cells was effective in the treatment of these patients. Some background Acute lymphoblastic leukemia (ALL) is a type of cancer of the bone marrow. This can lead to abnormal cells in the immune system. It is often...

Read More

Is blinatumomab safe and effective in the treatment of ALL?

Is blinatumomab safe and effective in the treatment of ALL?

Posted by on Nov 25, 2018 in Leukemia | 0 comments

In a nutshell This study looked at the safety and effectiveness of blinatumomab (Blincyto) in the treatment of unresponsive acute lymphoblastic leukemia (ALL). Researchers found that blinatumomab was safe and effective in the treatment of these patients. Some background Acute lymphoblastic leukemia is a type of cancer of the bone marrow. This can lead...

Read More

Is regorafenib a safe option for the treatment of metastatic colorectal cancer?

Is regorafenib a safe option for the treatment of metastatic colorectal cancer?

Posted by on Nov 22, 2018 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of regorafenib (Stivarga) to treat patients with metastatic (spread to other parts of the body) colorectal cancer (mCRC) that progressed after initial treatment. Researchers suggested that regorafenib is a safe option to treat these patients. Some background The standard treatment...

Read More

Evaluating survival outcomes after brentuximab vedotin treatment for relapsed or refractory Hodgkin’s lymphoma

Evaluating survival outcomes after brentuximab vedotin treatment for relapsed or refractory Hodgkin’s lymphoma

Posted by on Nov 22, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the impact of brentuximab vedotin (Adcetris) on the survival of patients with relapsed or refractory (does not respond to treatment) classical Hodgkin’s lymphoma (cHL). This study concluded that brentuximab vedotin significantly improved survival in these patients. Some background Patients with cHL who...

Read More

Evaluating the long-term outcomes of brentuximab vedotin after stem cell transplantation for classical Hodgkin’s lymphoma

Evaluating the long-term outcomes of brentuximab vedotin after stem cell transplantation for classical Hodgkin’s lymphoma

Posted by on Oct 29, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the long-term survival and safety of brentuximab vedotin (Adcetris) treatment for patients with classical Hodgkin’s lymphoma (cHL) after autologous stem cell transplantation (auto-SCT; patient's own healthy stem cells are retrieved and then returned into the body after cancer has been removed with chemotherapy...

Read More

Evaluating lenalidomide plus everolimus for relapsed or refractory lymphoma

Evaluating lenalidomide plus everolimus for relapsed or refractory lymphoma

Posted by on Oct 28, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the effectiveness and safety of lenalidomide (Revlimid) plus everolimus (Afinitor) in pretreated patients with relapsed (recurrent) or refractory (does not respond to treatment) lymphoma. This study concluded that this combination was well-tolerated and showed promising effectiveness in these patients. Some...

Read More

The safety of elotuzumab, lenalidomide and dexamethasone in unresponsive multiple myeloma.

The safety of elotuzumab, lenalidomide and dexamethasone in unresponsive multiple myeloma.

Posted by on Oct 18, 2018 in Multiple Myeloma | 0 comments

In a nutshell This paper compared the safety and effectiveness of elotuzumab (Empliciti) plus lenalidomide (Revlimid) and dexamethasone (Decadron) with lenalidomide and dexamethasone in unresponsive multiple myeloma. It was found that elotuzumab plus lenalidomide and dexamethasone was more effective than lenalidomide and dexamethasone alone. Some...

Read More

Can prednisone be replaced with dexamethasone in patients with prostate cancer treated with abiraterone acetate?

Can prednisone be replaced with dexamethasone in patients with prostate cancer treated with abiraterone acetate?

Posted by on Sep 29, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to investigate the use of dexamethasone, instead of prednisone, used with abiraterone acetate (Zytiga) for patients with metastatic castration-resistant prostate cancer (mCRPC). This study found that prednisone to dexamethasone switch can benefit some patients with mCRPC. Some background Androgen deprivation therapy...

Read More

Evaluating BendaEAM chemotherapy before stem cell transplantation for relapsed lymphoma

Evaluating BendaEAM chemotherapy before stem cell transplantation for relapsed lymphoma

Posted by on Sep 28, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of the BendaEAM (bendamustine, etoposide, cytarabine, melphalan) in patients with lymphoma undergoing autologous stem cell transplantation (auto-SCT). This study concluded that BendaEAM is a feasible option for these patients, with minimal side effects. Some background High-dose...

Read More

Evaluating venetoclax monotherapy for relapsed or refractory mantle cell lymphoma

Evaluating venetoclax monotherapy for relapsed or refractory mantle cell lymphoma

Posted by on Sep 27, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of venetoclax (Venclexta) monotherapy (single-agent treatment) in patients with relapsed (cancer recurrence) or refractory (does not respond to initial treatment) mantle cell lymphoma (MCL). This study concluded that venetoclax monotherapy is promising, with minimal side effects. Some...

Read More